Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices.

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices.

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.

Prognosis: Misconception

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

Learning to Love Big Pharma

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f12f184c-b83d-4020-bce5-ae390093e759/transcript